drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Patient-derived T cells genetically engineered to express a CD19-targeted chimeric antigen receptor (with CD3ζ/costimulatory signaling) and infused IV to eliminate CD19+ B cells, leading to B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a CD19-targeted chimeric antigen receptor with CD3ζ and costimulatory domains. Upon binding CD19 on malignant and normal B cells, CAR signaling activates T-cell cytotoxicity (perforin/granzyme), cytokine release, and expansion, leading to elimination of CD19+ cells and B-cell aplasia.
drug_name
Autologous anti-CD19 CAR T cells
nct_id_drug_ref
NCT06027957